Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Shah MS, Sharma VV, Patel SJ, Ansari AS. Retrospective evaluation of efficacy of CytoSorb® therapy in septic shock patients in a tertiary care intensive care unit. World J Crit Care Med 2025; 14(4): 105600 [PMID: 41377524 DOI: 10.5492/wjccm.v14.i4.105600]
World J Crit Care Med. Dec 9, 2025; 14(4): 105600 Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.105600
Retrospective evaluation of efficacy of CytoSorb® therapy in septic shock patients in a tertiary care intensive care unit
Mayur S Shah, Vedika V Sharma, Syed J Patel, Abdul S Ansari
Mayur S Shah, Vedika V Sharma, Syed J Patel, Abdul S Ansari, Critical Care Medicine, Nanavati Max Super Speciality Hospital, Mumbai 400056, Maharashtra, India
Author contributions: Ansari AS was involved in project supervision, guidance, conceptualization, research design, manuscript drafting, manuscript review, and manuscript finalization; Shah MS performed conceptualization, study design, data interpretation, manuscript writing, critical revision, and manuscript finalization; Sharma VV and Patel SJ for data collection, data analysis, manuscript writing, manuscript finalization.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of our institution (Approval no. BNH/2023/2019).
Informed consent statement: The informed consent is not applicable as the study under consideration is retrospective in nature, and the data involved in the entire process is completely anonymised.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Abdul S Ansari, MD, Director, Critical Care Medicine, Nanavati Max Super Speciality Hospital, Swami Vivekananda Road, Vile Parle (West), Mumbai 400056, Mahārāshtra, India. drabdulansari@gmail.com
Received: January 30, 2025 Revised: May 8, 2025 Accepted: August 6, 2025 Published online: December 9, 2025 Processing time: 303 Days and 22.1 Hours
Core Tip
Core Tip: CytoSorb® is an innovative extracorporeal cytokine hemoadsorption device designed to stabilize hemodynamic parameters and regulate the cytokine storm in sepsis. This retrospective study evaluated the efficacy of CytoSorb® hemoadsorption therapy as an adjunct to standard care in intensive care unit patients with septic shock. The findings indicate significant reductions in inflammatory biomarkers, vasopressor requirements, along with improvements in organ recovery and survival outcomes. Additionally, no major adverse events were reported in patients receiving the therapy. The study underscores CytoSorb® ability to modulate hyperinflammation from cytokine storms and stabilize hemodynamics, thus facilitating early shock reversal, and improving clinical outcomes in critically ill patients.
